Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Goodwill & Intangibles: 2018-2024

Historic Goodwill & Intangibles for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to $61.0 million.

  • Pharming Group N.V's Goodwill & Intangibles rose 101.09% to $134.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.9 million, marking a year-over-year increase of 101.09%. This contributed to the annual value of $61.0 million for FY2024, which is 14.35% down from last year.
  • As of FY2024, Pharming Group N.V's Goodwill & Intangibles stood at $61.0 million, which was down 14.35% from $71.3 million recorded in FY2023.
  • Pharming Group N.V's 5-year Goodwill & Intangibles high stood at $94.1 million for FY2020, and its period low was $61.0 million during FY2024.
  • Over the past 3 years, Pharming Group N.V's median Goodwill & Intangibles value was $71.3 million (recorded in 2023), while the average stood at $69.1 million.
  • Per our database at Business Quant, Pharming Group N.V's Goodwill & Intangibles increased by 18.49% in 2020 and then fell by 14.35% in 2024.
  • Yearly analysis of 5 years shows Pharming Group N.V's Goodwill & Intangibles stood at $94.1 million in 2020, then fell by 10.89% to $83.8 million in 2021, then dropped by 10.39% to $75.1 million in 2022, then declined by 5.13% to $71.3 million in 2023, then declined by 14.35% to $61.0 million in 2024.